| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Cell viability decreases in response to varying doses and times of exposure to bichopric acid (10–200 μM) [1]. Through the caspase-3 route, chicoric acid (100 μM; 48 h) is induced by chicoric acid (100 μM; 48 h) to lower the protein level of p-Akt [1]. In a dosed way, chimerric acid (25, 50, or 100 μM) greatly enhanced nutritional dosage for 24 hours. , and chicoric acid improved insulin-induced supplementing to 57.7% of HepG2 cells (100 nM; 30 minutes) [2]. In HepG2 cells, chichoric acid (100 μM; 24 hours) effectively activated PI3K/Akt, restoring ischemia signaling. The viability of HepG2 cells was unaffected by chichoric acid at 100 μM [2].
|
|---|---|
| ln Vivo |
Streptozotocin (STZ; 5 0 mg/kg; intraperitoneally) is used as a result of the inhibition of the pancreatic cell lateral wall of the diabetic renal pelvis and modulation of islet function caused by choric acid (60 mg/kg/day; 4 weeks with drinking water).
|
| Cell Assay |
Cell viability assay[1]
Cell Types: 3T3-L1 preadipocyte Tested Concentrations: 10-200 μM Incubation Duration: 24, 48 GLUT2 translocation injury[2]. and 72 hrs (hours) Experimental Results: 10-50μM for 24 hrs (hours) had no effect on the viability of 3T3-L1 preadipocytes, but 100μM and 200μM Dramatically diminished cell viability. Apoptosis analysis [1] Cell Types: 3T3-L1 preadipocyte Tested Concentrations: 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: DAPI and AO/EB staining demonstrated typical cell shrinkage, chromatin condensation, and increased cell membrane permeability. characteristics of apoptosis. Western Blot Analysis[1] Cell Types: 3T3-L1 Preadipocytes Tested Concentrations: 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: p-Akt protein levels diminished in a dose- and time-dependent manner. Total Akt protein levels are not affected |
| Animal Protocol |
Animal/Disease Models: C57BL/6J mice The generation and death of C57BL/6J mice with STZ (50 mg/kg; ip; for 5 days) [3]. kg
Route of Administration: drinking water; daily; continued for 4 weeks Experimental Results: Inhibited pancreatic cell apoptosis and adjusted pancreatic islet function in diabetic mice, resulting in increased insulin production and secretion. Regulates mitochondrial biogenesis, glycogen synthesis and suppresses inflammation by activating antioxidant responses. From the 7th week onwards, there was a significant weight gain. |
| References |
|
| Additional Infomation |
Chicoric acid is an organooxygen compound. It has a role as a HIV-1 integrase inhibitor and a geroprotector. It is functionally related to a tetracarboxylic acid.
Chicoric acid has been reported in Camellia sinensis, Hydrastis canadensis, and other organisms with data available. |
| Molecular Formula |
C22H18O12
|
|---|---|
| Molecular Weight |
474.3711
|
| Exact Mass |
474.079
|
| CAS # |
6537-80-0
|
| Related CAS # |
L-Chicoric Acid;70831-56-0
|
| PubChem CID |
5281764
|
| Appearance |
White to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
785.0±60.0 °C at 760 mmHg
|
| Flash Point |
272.9±26.4 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.726
|
| LogP |
3.81
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
34
|
| Complexity |
740
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC(=C(C=C1/C=C/C(=O)O[C@@H](C(=O)O)[C@@H](OC(=O)/C=C/C2=CC(=C(C=C2)O)O)C(=O)O)O)O
|
| InChi Key |
YDDGKXBLOXEEMN-IABMMNSOSA-N
|
| InChi Code |
InChI=1S/C22H18O12/c23-13-5-1-11(9-15(13)25)3-7-17(27)33-19(21(29)30)20(22(31)32)34-18(28)8-4-12-2-6-14(24)16(26)10-12/h1-10,19-20,23-26H,(H,29,30)(H,31,32)/b7-3+,8-4+/t19-,20-/m1/s1
|
| Chemical Name |
(2R,3R)-2,3-bis[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~210.81 mM)
DMSO : ~1 mg/mL (~2.11 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (105.40 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1081 mL | 10.5403 mL | 21.0806 mL | |
| 5 mM | 0.4216 mL | 2.1081 mL | 4.2161 mL | |
| 10 mM | 0.2108 mL | 1.0540 mL | 2.1081 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
